KRAS and glioblastoma: If repair of the alkylating lesions does not complete entirely, a G → A transition mutation or a strand break can occur, resulting in oncogene mutations in pre-malignant lesions (e.g. KRAS point mutations), or futile cycles of repair that triggers apoptosis (outcome of therapeutic treatment such as Temozolomide in glioblastoma), respectively47,48.